Horizon Pharma may be weak on Ravicti settlement, says Mizuho. Mizuho analyst Irina Koffler expects “slight weakness” in shares of Horizon Pharma after the company announced a 2026 Ravicti generic settlement. However, after speaking with physicians and Horizon management about Krystexxa and its growth strategies, and the analyst reiterates a Buy rating on the shares with an $18 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.